|Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA||Founder, CEO & Director||607.95k||N/A||1969|
|Ms. Samira Sakhia BCom, MBA, CPA, CA||Pres & Director||616.21k||N/A||1968|
|Mr. Arvind Utchanah||Chief Financial Officer||354.32k||N/A||N/A|
|Ms. Amal Khouri M.B.A.||VP of Bus. Devel.||517.23k||N/A||N/A|
|Ms. Jody Engel||Sr. Director of Bus. Devel.||218.59k||N/A||N/A|
|Mr. Michel Loustric||Pres of Knight Barbados||N/A||N/A||N/A|
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Knight Therapeutics Inc.’s ISS governance QualityScore as of 1 December 2020 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 2; Compensation: 6.